Effect of polyphenol-rich grape seed extract on ambulatory blood pressure in subjects with pre- and stage I hypertension

Rouyanne T. Ras1*, Peter L. Zock1,2, Yvonne E. M. P. Zebregs1, Neil R. Johnston3, David J. Webb3 and Richard Draijer1
1Unilever R&D Vlaardingen, Olivier van Noortlaan 120, 3133 AT, Vlaardingen, The Netherlands
2Top Institute Food and Nutrition, Nieuwe Kanaal 9a, 6709 PA, Wageningen, The Netherlands
3British Heart Foundation Centre of Research Excellence, University of Edinburgh, Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK

(Submitted 20 November 2012 – Final revision received 4 April 2013 – Accepted 21 April 2013 – First published online 23 May 2013)

Abstract
Dietary polyphenols, such as those from grape products, may exert beneficial effects on cardiovascular health, including anti-hypertensive effects. We investigated the effect of a specific grape seed extract (GSE) rich in low-molecular-weight polyphenolic compounds on ambulatory blood pressure (ABP) in untreated subjects with pre- and stage I hypertension. In addition, potential mechanisms that could underlie the hypothesised effect of GSE on blood pressure (BP), and platelet aggregation, were explored. The study was designed as a double-blind, placebo-controlled, randomised, parallel-group intervention study including seventy healthy subjects with systolic BP between 120 and 159 mmHg. A 1-week run-in period was followed by an 8-week intervention period, during which subjects consumed capsules containing either 300 mg/d of GSE or a placebo (microcrystalline cellulose). Before and after the intervention, daytime ABP readings, 24 h urine samples and fasting and non-fasting blood samples were taken. The mean baseline systolic BP was 135·8 (SE 1·3) mmHg and diastolic BP was 81·5 (SE 0·9) mmHg. BP values were modestly, but not significantly, affected by the polyphenol-rich GSE treatment. placebo with an effect of −3·0 mmHg for systolic BP (95% CI −6·5, 0·5) and −1·4 mmHg for diastolic BP (95% CI −3·5, 0·6). Vasoactive markers including endothelin-1, NO metabolites and asymmetric dimethylarginine, plasma renin activity and platelet aggregation were not affected by the GSE intervention. Our findings show that consumption of polyphenol-rich GSE does not significantly lower ABP in untreated subjects with pre- and stage I hypertension.

Key words: Blood pressure; Grape seed extract; Dietary intervention studies; Cardiovascular health

High blood pressure (BP) is a global public health problem(1). BP is strongly associated with age-specific mortality rates from stroke, IHD and other vascular causes, even at the lower levels of the distribution (down to 115/75 mmHg)(2). It has been estimated that an average reduction in BP of 2 mmHg at the population level might reduce mortality from stroke by about 10 %, and mortality from IHD or other vascular diseases by about 7 %(2).

Polyphenols are a wide class of bioactive compounds abundant in plant foods such as fruits, cereals, legumes and vegetables. In population studies, lower cardiovascular event rates were observed in subjects with a higher consumption of flavonoids, i.e. polyphenols with a C6−C3−C6 basic structure(3–6). Grape products contain polyphenols, such as anthocyanins, flavanols and flavonols, as well as phenolic acids(7). The effects of grape products on cardiovascular risk markers have been reported in several human intervention studies and include an improvement in plasma lipid profiles(8,9), an enhancement of endothelial function(10–14) and an inhibition of platelet aggregation(15–17). For the effects of grape products on BP, evidence was not convincing in some of the human studies(10,18–20), while other human studies have shown beneficial effects on BP(14,21,22) or on its nocturnal dip(23). Recent clinical evidence has shown that other flavonol-rich foods such as dark chocolate and black tea may also lower BP in hypertensive populations(24,25).

In grapes, the highest concentrations of polyphenols are found in the skin, stems and seeds. Sivaprakasapillai et al.1(22) recently reported that a specific grape seed extract (GSE) reduced BP by 9 mmHg v. placebo in metabolic syndrome patients. Due to a specific extraction method, this GSE consists mainly of polyphenols (approximately 80 % of the dry weight) with an enhanced content of monomeric and oligomeric polyphenols. Also, levels of gallic acid and de-gallated catechins

Abbreviations: ABP, ambulatory blood pressure; ADMA, asymmetric dimethylarginine; BP, blood pressure; DBP, diastolic blood pressure; ET-1, endothelin-1; GSE, grape seed extract; SBP, systolic blood pressure.

* Corresponding author: R. T. Ras, fax +31 10 460 5993, email rouyanne.ras@unilever.com
are increased due to a tannase treatment. Thus, this GSE extract has, compared with other polyphenol extracts, relatively high concentrations of low-molecular-weight phenolic compounds, which are probably more bioavailable than large polymeric polyphenols \(^{22,26,27}\). Therefore, this specific GSE seemed promising and possibly more effective than other GSE in lowering BP.

The metabolic mechanisms by which polyphenol-rich extracts and foods could affect BP are not well understood, although several pathways have been suggested. In the present study, we explored these pathways including the following: potent vasoconstrictor endothelin-1 (ET-1) \(^{28,29}\); metabolites of NO which modulate vascular tone and reactivity \(^{30}\); asymmetric dimethylarginine (ADMA) which inhibits the production of NO by competing with l-arginine as the substrate for endothelial NO synthesis \(^{31}\); plasma renin activity which indicates the influences on, or actions through, the renin–angiotensin system. We also explored the possible effects of GSE on platelet function. Platelet function plays a prominent role in defining CVD risk \(^{32}\), and some studies have shown that grape polyphenols may reduce platelet aggregation \(^{15–17}\).

Thus, in the present study, we investigated the effects of an encapsulated GSE, rich in low-molecular-weight polyphenolic compounds, on daytime ambulatory systolic BP (SBP) and diastolic BP (DBP) in untreated subjects with pre- and stage I hypertension. Furthermore, we explored some mechanistic pathways that are possibly involved in the BP-lowering efficacy of GSE, as well as the effect of GSE on platelet aggregation.

**Experimental methods**

The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the Medical Ethics Committee of Wageningen University, The Netherlands. The study was conducted according to the Dutch Medical Research Involving Human Subjects Act and the International Conference on Harmonisation Guidelines for Good Clinical Practice. The study took place from April to July 2009 at Unilever R&D Vlaardingen, The Netherlands. Written informed consent was obtained from all subjects. The study was registered at ClinicalTrials.gov (identifier no. NCT00869193).

**Study population**

In the present study, seventy male and postmenopausal female subjects were recruited. Subjects were eligible when they met the following main selection criteria: aged 35–75 years; no reported current or previous metabolic diseases, chronic gastrointestinal disorders or cardiovascular or renal diseases; having slightly elevated BP ranging between 120 and 159 mmHg (120 mmHg is the upper threshold for a normal BP, whereas 159 mmHg is the upper threshold for hypertension stage I \(^{33}\) and was taken as a cut-off point to avoid the inclusion of subjects probably requiring anti-hypertensive therapy) and DBP < 100 mmHg; having a BMI between 18.5 and 30 kg/m\(^2\); having no or willing to refrain from lifestyle habits that could have an impact on BP including extreme physical exercise and the consumption of polyphenol-rich foods and/or supplements; no use of medication that could influence the study outcomes (BP-lowering drugs, antibiotics, acetylsalicylic acid or similar-type painkillers); having ≤ 30% error readings during the 6 h ambulatory BP (ABP) measurements at screening; having signed the informed consent.

**Study design**

The present study was designed as a double-blind, placebo-controlled, randomised, parallel-group study with a 1-week run-in period (days 1–7) and an 8-week intervention period (days 8–65). Subjects were randomly allocated to receive either capsules with GSE (n = 35) or placebo capsules (n = 35). A statistician randomised the personal codes to one of the two different treatments while stratifying the subjects according to sex. Pre- and post-intervention, subjects visited the test facility on three consecutive test days (days 5–7 and 61–65, respectively). Daytime ABP measurements were conducted on days 5, 7, 61 and 63. On days 6 and 62, 24 h urine was collected (until the mornings of days 7 and 63, respectively) and blood samples were drawn in the fasted state (before breakfast) and in the non-fasted state (2 h after breakfast (+capsule)). A standardised breakfast was served on all six test days. To check compliance and the subjects’ well-being, and to encourage them to follow the protocol as requested, subjects visited the test facility 2 weeks after the start of the intervention, and they were reminded by telephone after 5 weeks.

**Test products and dietary instructions**

Subjects consumed either gelatin capsules (size 0) containing 300 mg GSE (MegaNatural BP\(^\text{®}\); Polyphenolics) or microcrystalline cellulose as placebo (excipients were used in equal amounts in both test products). As published by Edirisinghe et al. \(^{34}\), the distribution of phenolic compounds in this GSE was expected to be on average 9% monomers, 69% oligomers and 22% polymers. Capsules were produced by Metagenics. Based on the \(^1\)H NMR technique and the Folin–Ciocalteu method, the polyphenol content of the pure GSE was determined to be 77–80% (as expressed in free gallic acid equivalents). We were able to identify only 18% of the polyphenols; the major identified compounds were monomeric procyanidin (catechins) (43%), dimeric procyanidins (61%), trimeric procyanidins (25%) and gallic acid (48%), whereas minor compounds were galloylated catechins (0.3%), flavonoids (0.02%) and stilbenes (0.003%). Unidentified polyphenols probably included oligomers and polymers that are more difficult to identify. Compared with the amounts of 5–15% monomeric procyanidins reported for other batches of this GSE \(^{34}\), the identified amount of monomeric procyanidins in the batch used in the present study was at the lower end of the range. The placebo capsules did not contain any detectable polyphenols. Test products were microbiologically
checked (analysis of total viable count, enterobacteriaceae, yeasts and moulds) before providing them in blister packs to the subjects. Test and placebo capsules were identical with respect to size and colour. The treatment code of the two test products was blinded for subjects and all staff involved in the study.

Subjects were instructed to consume one capsule per d, in the morning directly after breakfast, receiving the final dose on the last test day (day 63). They were asked to maintain their normal diet and lifestyle during the study, but to refrain from a selection of foods that are typically rich in polyphenols, i.e. dark chocolate, red wine and grape juice, and to restrict consumption of tea and red fruit to a maximum of two servings per d each. We deliberately avoided restrictive intake of all polyphenol-containing foods, because this would have had an impact on the subjects’ diet and lifestyle behaviour in such a way that it may have interfered with the treatment effect. At 36 h before each test day until the end of the test occasion, drinking alcoholic beverages was not allowed. Food intake was standardised on all the six test days. This was done by complete 3 d dietary records of individual food intakes on days 5, 6 and 7, and by the instruction to repeat this food pattern on days 61, 62 and 63, respectively. Any deviations from the dietary instructions and protocol were recorded by the subjects in their personal diaries. In addition, subjects kept daily written records of their test product intake. At the end of the intervention, subjects returned all empty blister packs and any unused capsules. These were counted to estimate compliance.

Measurements

Daytime ABP and heart rate recordings were taken every 20 min between 08.30 and 20.30 hours, using an ABP monitor (Spacelabs monitor type 90 217; Spacelabs Healthcare) on the non-dominant arm. Breakfast was consumed shortly (within 30 min) before the start of the daytime ABP recordings. Subjects were asked to refrain from any strenuous exercise and to follow their habitual daily living and working pattern on the last test day (day 63). They were asked to maintain their normal diet and lifestyle during the study, but to refrain from a selection of foods that are typically rich in polyphenols, i.e. dark chocolate, red wine and grape juice, and to restrict consumption of tea and red fruit to a maximum of two servings per d each. We deliberately avoided restrictive intake of all polyphenol-containing foods, because this would have had an impact on the subjects’ diet and lifestyle behaviour in such a way that it may have interfered with the treatment effect. At 36 h before each test day until the end of the test occasion, drinking alcoholic beverages was not allowed. Food intake was standardised on all the six test days. This was done by complete 3 d dietary records of individual food intakes on days 5, 6 and 7, and by the instruction to repeat this food pattern on days 61, 62 and 63, respectively. Any deviations from the dietary instructions and protocol were recorded by the subjects in their personal diaries. In addition, subjects kept daily written records of their test product intake. At the end of the intervention, subjects returned all empty blister packs and any unused capsules. These were counted to estimate compliance.

Blood sampling was done in the fasted state (overnight fast of at least 10 h) and in the non-fasted state (2 h after a served breakfast (+ capsule)). In the fasted state, one hirudin tube was collected for determining platelet aggregation based on the single platelet count method ($^{2}$) using four different agonists (HEPES, adenosine di-phosphate, collagen and thrombin receptor-activating protein). This assessment required immediate analysis after sample collection. K3-EDTA tubes were collected for measuring NO metabolites by nitrate and nitrite assays, ET-1 by RIA using commercial human ET-1 antibody (Bachem) and radiolabelled ET-1 (Perkin-Elmer), ADMA by using a competitive ADMA-ELISA (DLD Diagnostika) and plasma renin activity by a commercial RIA kit (Dia Sorin). In the non-fasted state, additional K3-EDTA tubes were collected for measuring NO metabolites, ET-1, ADMA and plasma renin activity. Urine was collected during 24 h. The subjects stored the non-acidified urine at room temperature. When the collected urine was handed in, it was immediately homogenised and weighed and samples were taken for measuring ET-1 and NO metabolites as described above. Na and K contents were measured using the Hitachi 912 auto-analyser (Rochi Diagnostics), and polyphenol metabolites were measured using a GC/MS (Agilent). More detailed information on blood analyses and 24 h urine analyses is provided in the Supplementary Material (available online). All samples, except those required for assessing platelet aggregation, were stored at -80°C until analysis.

Adverse events were recorded on a case report form and classified according to the International Classification of Diseases, ninth revision (ICD-9).

Statistics

With seventy subjects in the study and assuming a within-subject variation of 30 mmHg for duplicate ABP measurements, the study had a statistical power of 80% to detect a mean SBP reduction of 3·7 mmHg ($a = 0·05$; two-sided). Data were analysed according to both the intention-to-treat principle and the per-protocol principle excluding data from subjects for which events outside the protocol might have affected the validity of the outcomes. Here, we report the results based on the intention-to-treat analysis only; the per-protocol analysis yielded similar results.

Differences in the changes from baseline in ABP and heart rate between active treatment and placebo were statistically analysed with a repeated-measurements mixed-model analysis (the average per h was included). Treatment, sex, date of inclusion in the trial and hour of BP measurement were included as fixed factors. Age, BMI, change in body weight, change in Na, K and Na:K ratio were included as covariates. Subjects were included as a random factor. A banded Toeplitz$^{2}$ covariance structure was assumed. The model was simplified by backward elimination; variables were only retained when their significance was below 0·10. Differences in changes in secondary parameters were explored by means of an ANCOVA. P values are based on two-sided testing. Statistical analyses were performed using SAS software (SAS Institute, version 9.2).

Results

Subjects and compliance

Of the 190 subjects that underwent actual screening, eighty-four subjects were eligible for the study. Of these, ten subjects were randomly excluded and four subjects were assigned to be spare subjects to allow for some dropout before the start of the intervention. During the run-in period, one subject dropped out for personal reasons and was replaced by a spare subject. Finally, seventy healthy subjects, thirty-eight males (54%) and thirty-two (46%) females, were randomised to active or placebo treatments. An overview of the subjects’ characteristics is provided in Table 1. During the intervention, one subject dropped out due to the prescription of BP-lowering medication. Count of returned capsules indicated an almost
Characteristics of the study population at screening

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>GSE group</th>
<th>Placebo group</th>
<th>All subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>25·3 0·4</td>
<td>25·7 0·5</td>
<td>25·5 0·3</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>76·1 1·9</td>
<td>77·9 2·2</td>
<td>77·0 1·5</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>173·0 1·7</td>
<td>173·8 1·7</td>
<td>173·4 1·2</td>
</tr>
</tbody>
</table>

At baseline, the mean daytime ambulatory SBP was 135·8 (SE 1·9) mmHg and DBP 81·5 (SE 0·9) mmHg. After 8 weeks of intervention, SBP was changed by 2·8 (95 % CI 0·2, 5·4) mmHg for SBP and 2·5 (95 % CI 1·0, 4·0) mmHg for DBP (Table 2 and Fig. 1). Heart rate was not significantly affected by the GSE treatment (95 % CI 1·0, 2·8, 2·9).

At baseline, the mean daytime ambulatory SBP was 135·8 (SE 1·9) mmHg and DBP 81·5 (SE 0·9) mmHg. After 8 weeks of intervention, SBP was changed by 2·8 (95 % CI 0·2, 5·4) mmHg for SBP and 2·5 (95 % CI 1·0, 4·0) mmHg for DBP (Table 2 and Fig. 1). Heart rate was not significantly affected by the GSE treatment (95 % CI 1·0, 2·8, 2·9).

Daytime ambulatory blood pressure and heart rate

At baseline, the mean daytime ambulatory SBP was 135·8 (SE 1·9) mmHg and DBP 81·5 (SE 0·9) mmHg. After 8 weeks of intervention, SBP was changed by 2·8 (95 % CI 0·2, 5·4) mmHg for SBP and 2·5 (95 % CI 1·0, 4·0) mmHg for DBP (Table 2 and Fig. 1). Heart rate was not significantly affected by the GSE treatment (95 % CI 1·0, 2·8, 2·9).

Adverse events

The reported adverse events were mild and the incidence was low (n 71), with major complaints being headache (n 16), joint pain or lumbago (n 6), allergic rhinitis (n 5) and (naso-) pharyngitis (n 4). Between the two treatment groups, there was no statistically significant difference in the number of subjects reporting adverse events and in the nature and frequency of these events.

Table 2. Ambulatory blood pressure and heart rate (HR)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Treatment</th>
<th>Subjects (n)</th>
<th>Baseline</th>
<th>Endpoint</th>
<th>Change*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean (SE)</td>
<td>Mean (SE)</td>
<td>Mean (95 % CI)</td>
<td>P</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>GSE</td>
<td>34</td>
<td>135·8 1·9</td>
<td>130·3 1·7</td>
<td>-5·2 -7·7, -2·8 &lt;0·01</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>35</td>
<td>135·7 1·7</td>
<td>132·5 1·7</td>
<td>-2·2 -4·7, 0·2 0·07</td>
</tr>
<tr>
<td></td>
<td>Δ</td>
<td>69</td>
<td>-3·0 -6·5, 0·5 0·09</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>GSE</td>
<td>34</td>
<td>81·9 1·5</td>
<td>79·1 1·3</td>
<td>-2·5 -4·0, -1·0 &lt;0·01</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>35</td>
<td>81·1 1·2</td>
<td>80·0 1·1</td>
<td>-1·1 -2·5, 0·4 0·14</td>
</tr>
<tr>
<td></td>
<td>Δ</td>
<td>69</td>
<td>-1·4 -3·6, 0·6 0·18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>GSE</td>
<td>34</td>
<td>72·6 1·5</td>
<td>73·0 1·7</td>
<td>0·5 -1·5, 2·5 0·61</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>35</td>
<td>72·3 1·5</td>
<td>72·2 1·3</td>
<td>0·5 -1·5, 2·5 0·61</td>
</tr>
<tr>
<td></td>
<td>Δ</td>
<td>69</td>
<td>0·0 -2·8, 2·9 1·00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SBP, systolic blood pressure; GSE, grape seed extract; DBP, diastolic blood pressure; bpm, beats per min.
* Adjusted model; change adjusted for baseline values and covariates with P<0·05 for SBP, change in weight and change in ratio Na:K for DBP, sex and age; for HR, sex, age and change in ratio Na:K.

Vasoactive biomarkers, plasma renin activity and platelet aggregation

Compared with placebo, the GSE intervention did not significantly affect plasma and urine concentrations of the vasoconstrictor ET-1 and of the endogenous NO metabolites nitrite and nitrate. Also, plasma concentrations of ADMA and the activity of plasma renin were not significantly affected by the GSE treatment (Table 3). Additionally, 8 weeks of GSE intervention did not change platelet aggregation as induced by several agonists when compared with placebo, except for a modest reduction in platelet aggregation after 1 min of HEPES stimulus (change in the amount of free platelets: 5·4 % (95 % CI 0·2, 10·7)).

Urinary phenolic metabolite excretion

Based on a principal component analysis, the urinary phenolic acids that contributed most to correctly classifying subjects in the GSE and placebo groups were 4-O-methylgallic acid, 3-hydroxymandelic acid, 3,3-hydroxyphenylacetic acid, pyrogallol, vanillic acid, 3,4-dimethoxyphenylacetic acid, ferulic acid and caffeic acid. Of these, only 4-O-methyl gallic acid and pyrogallol were significantly increased in the GSE group compared with the placebo group (ratio GSE: placebo: 4·7 (95 % CI 3·8, 5·8) and 2·0 (95 % CI 1·5, 2·7), respectively). Out of forty-five metabolites, six metabolites showed weak (<0·2|R| < 0·5) correlations with SBP changes and two with DBP changes, which we considered not biologically meaningful.

Adverse events

The reported adverse events were mild and the incidence was low (n 71), with major complaints being headache (n 16), joint pain or lumbago (n 6), allergic rhinitis (n 5) and (naso-) pharyngitis (n 4). Between the two treatment groups, there was no statistically significant difference in the number of subjects reporting adverse events and in the nature and frequency of these events.

Table 2. Ambulatory blood pressure and heart rate (HR)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Treatment</th>
<th>Subjects (n)</th>
<th>Baseline</th>
<th>Endpoint</th>
<th>Change*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean (SE)</td>
<td>Mean (SE)</td>
<td>Mean (95 % CI)</td>
<td>P</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>GSE</td>
<td>34</td>
<td>135·8 1·9</td>
<td>130·3 1·7</td>
<td>-5·2 -7·7, -2·8 &lt;0·01</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>35</td>
<td>135·7 1·7</td>
<td>132·5 1·7</td>
<td>-2·2 -4·7, 0·2 0·07</td>
</tr>
<tr>
<td></td>
<td>Δ</td>
<td>69</td>
<td>-3·0 -6·5, 0·5 0·09</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>GSE</td>
<td>34</td>
<td>81·9 1·5</td>
<td>79·1 1·3</td>
<td>-2·5 -4·0, -1·0 &lt;0·01</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>35</td>
<td>81·1 1·2</td>
<td>80·0 1·1</td>
<td>-1·1 -2·5, 0·4 0·14</td>
</tr>
<tr>
<td></td>
<td>Δ</td>
<td>69</td>
<td>-1·4 -3·6, 0·6 0·18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>GSE</td>
<td>34</td>
<td>72·6 1·5</td>
<td>73·0 1·7</td>
<td>0·5 -1·5, 2·5 0·61</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>35</td>
<td>72·3 1·5</td>
<td>72·2 1·3</td>
<td>0·5 -1·5, 2·5 0·61</td>
</tr>
<tr>
<td></td>
<td>Δ</td>
<td>69</td>
<td>0·0 -2·8, 2·9 1·00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SBP, systolic blood pressure; GSE, grape seed extract; DBP, diastolic blood pressure; bpm, beats per min.
* Adjusted model; change adjusted for baseline values and covariates with P<0·05 for SBP, change in weight and change in ratio Na:K for DBP, sex and age; for HR, sex, age and change in ratio Na:K.
not statistically significant and much smaller than the 9 mmHg reduction in SBP that has been previously reported for this specific GSE(22). Because we anticipated a larger BP-lowering effect based on this previous finding(22), the present study was not sufficiently powered to pick up more modest effects. Nevertheless, a 3 mmHg reduction in SBP would be clinically meaningful when considered at the population level, particularly in view of the large population of people with pre- and stage I hypertension. Further studies should therefore confirm or reject more modest effects of GSE on BP.

The composition of the GSE used in the present study is unique because of its high content of low-molecular-weight phenolic compounds, which should theoretically increase bioavailability(26). Unfortunately, the GSE batch used in the present study possibly contained lower levels of monomeric procyanidins (4%) compared with what has been seen in other batches (5–15%) (34). We cannot exclude that this may have influenced the efficacy of the GSE used in the present study. The present study was not specifically designed to investigate the bioavailability and metabolism of polyphenol compounds, as this would require multiple blood sampling over the day. Nevertheless, we estimated urinary excretion of polyphenol metabolites over a 24 h sampling period. Up to four times higher levels of urinary phenolic acids were detected in the GSE group vs. the placebo group, indicating that at least part of the polyphenol compounds or their metabolites formed in the body’s tissues or by the colonic microbiota(36) must have reached the circulation.

To our knowledge, five earlier human studies on GSE and BP have been published(10,18–20,22), as summarised by Feringa et al.(37). The majority of these studies, applying GSE doses ranging from 150 to 2000 mg/d during 2–12 weeks, have

**Discussion**

The findings of the present study suggest that polyphenol-rich GSE has no major effect on BP in subjects with pre- and stage I hypertension. The 3 mmHg fall in SBP that we observed was

**Table 3.** Vasoactive biomarkers and plasma renin activity

(Mean values with their standard errors; 95% confidence intervals)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Status</th>
<th>Treatments</th>
<th>Baseline Mean ± SE</th>
<th>Change Mean ± 95% CI</th>
<th>Δ Change* Mean ± 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma ET-1 (pg/ml)</td>
<td>Fasted</td>
<td>GSE</td>
<td>3.34 ± 0.09</td>
<td>−0.04</td>
<td>−0.15, 0.08</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo</td>
<td>3.38 ± 0.10</td>
<td>−0.10</td>
<td>−0.21, 0.02</td>
</tr>
<tr>
<td></td>
<td>Non-fasted</td>
<td>GSE</td>
<td>3.22 ± 0.10</td>
<td>−0.07</td>
<td>−0.08, 0.22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo</td>
<td>3.28 ± 0.11</td>
<td>−0.01</td>
<td>−0.16, 0.13</td>
</tr>
<tr>
<td>Urinary ET-1 (ng/24 h)</td>
<td>GSE</td>
<td>6.62 ± 0.43</td>
<td>−0.48</td>
<td>−1.40, 0.44</td>
<td>−0.30, −1.59, 0.99</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>6.39 ± 0.34</td>
<td>−0.18</td>
<td>−1.09, 0.72</td>
<td></td>
</tr>
<tr>
<td>Plasma NOx (µmol/l)</td>
<td>Fasted</td>
<td>GSE</td>
<td>32.13 ± 1.76</td>
<td>0.84</td>
<td>−3.37, 5.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo</td>
<td>31.45 ± 2.17</td>
<td>2.91</td>
<td>−1.18, 6.99</td>
</tr>
<tr>
<td></td>
<td>Non-fasted</td>
<td>GSE</td>
<td>29.52 ± 1.47</td>
<td>0.51</td>
<td>−2.64, 3.66</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo</td>
<td>28.12 ± 1.48</td>
<td>0.97</td>
<td>−2.08, 4.03</td>
</tr>
<tr>
<td>Urinary NOx (mmol/24 h)†</td>
<td>GSE</td>
<td>1.19 ± 0.10</td>
<td>−0.00</td>
<td>−0.18, 0.18</td>
<td>0.10, −0.15, 0.34</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>1.17 ± 0.11</td>
<td>−0.08</td>
<td>−0.27, 0.10</td>
<td></td>
</tr>
<tr>
<td>ADMA (µmol/l)†</td>
<td>Fasted</td>
<td>GSE</td>
<td>0.84 ± 0.03</td>
<td>0.03</td>
<td>−0.01, 0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo</td>
<td>0.83 ± 0.03</td>
<td>0.04</td>
<td>0.01, 0.08</td>
</tr>
<tr>
<td>ADMA (µmol/l)†</td>
<td>Non-fasted</td>
<td>GSE</td>
<td>0.86 ± 0.04</td>
<td>0.01</td>
<td>−0.03, 0.04</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo</td>
<td>0.85 ± 0.03</td>
<td>0.00</td>
<td>−0.03, 0.03</td>
</tr>
<tr>
<td>PRA (ng/ml per h)</td>
<td>Fasted</td>
<td>GSE</td>
<td>0.78 ± 0.07</td>
<td>0.09</td>
<td>−0.03, 0.22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo</td>
<td>0.76 ± 0.07</td>
<td>0.01</td>
<td>−0.12, 0.13</td>
</tr>
<tr>
<td>PRA (ng/ml per h)†</td>
<td>Non-fasted</td>
<td>GSE</td>
<td>0.98 ± 0.10</td>
<td>0.10</td>
<td>−0.14, 0.33</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo</td>
<td>0.98 ± 0.09</td>
<td>0.05</td>
<td>−0.08, 0.17</td>
</tr>
</tbody>
</table>

ET-1, endothelin-1; GSE, grape seed extract; NOx, NO metabolites; ADMA, asymmetric dimethylarginine; PRA, plasma renin activity.

* Adjusted model: change adjusted for baseline concentration and covariates with P<0.1.
† Extreme outliers (urinary nitrite > 80 µmol/l) were excluded (n 4).
failed to show a significant effect of GSE on BP in various populations (e.g. healthy adults, hypertensives, hypercholesterolaemics). Although these studies did not find significant effects, average SBP and DBP were in almost all studies slightly lower after a GSE intervention than after a placebo\(^{18–20}\), which is in agreement with the present results. Only Sivaprakasapillai et al.\(^{122}\) reported a large significant reduction in daytime SBP of about 9 mmHg \(v.\) placebo in metabolic syndrome patients after 4 weeks of intervention with 150 and 300 mg/d of GSE. In this study and in the present study, the same GSE was used as the active ingredient. The discrepancy in findings between the studies may be explained by differences in study populations. First, subjects in the present study were presumably healthier than the metabolic syndrome patients included in the study by Sivaprakasapillai et al.\(^{122}\). Second, the total polyphenol intake from the background diet was possibly higher in our Dutch population compared with their US population, which may have attenuated polyphenol-induced effects on BP in the present study.

The main regulators of BP, such as the renin–angiotensin–aldosterone system and the concentrations of cortisol and catecholamines, follow certain circadian rhythms\(^{50,59}\). Therefore, the timings of administration of a substance acting on this pathway may be important to elicit a response on BP\(^{50}\). The once-daily administration of the test products in the present study might therefore have affected the outcomes of the study.

We did not measure BP during night-time and could thus potentially have missed a nocturnal effect as reported earlier with a high dose of polyphenol-rich grape juice consumed during breakfast and dinner\(^{23}\). We cannot exclude that GSE at higher intake levels or administered in multiple doses throughout the day would have resulted in more pronounced BP effects.

Several mechanisms by which GSE could affect BP have been suggested. In one study in rats, it has been demonstrated that red wine extract (Provinols) lowered BP via an NO synthesis-dependent pathway\(^{51}\). Also, \textit{in vitro} studies have indicated the effects of GSE on NO availability\(^{34,42}\). NO is released in response to a variety of chemical and physical stimuli and causes the smooth muscle in the vessel wall to relax. In addition, cellular studies with wine polyphenols have indicated that these compounds may inhibit the generation of ET-1\(^{45}\), which is a potent vasoconstrictor\(^{28,44}\). These findings are in line with a human study showing that specific polyphenols can reduce ET-1 concentrations and increase NO status\(^{45}\). Additionally, reduction of plasma levels of ADMA may improve vessel wall function and lower BP by increasing NO bioavailability\(^{51}\). Degradation of ADMA occurs via dimethylarginine dimethylaminohydrolase, an enzyme that converts ADMA into citrulline and dimethylarginine. Polyphenol-rich products may decrease ADMA levels and increase dimethylarginine dimethylaminohydrolase activity\(^{46,47}\). In the present study, plasma NO metabolites, ET-1 and ADMA were unaffected by the GSE treatment, which would not support that these markers can explain a possible relationship between GSE and BP. However, in view of the only modest and non-significant difference in BP, the present study was probably not suited to demonstrate small changes in these markers.

At least two studies\(^ {15,16}\) have shown an inhibition of platelet aggregation after consumption of grape products (5–7.5 ml purple grape juice/kg body weight per d with approximately 2.26 g/l gallic acid equivalents) in healthy subjects. In the present study, inhibition of platelet aggregation could not be demonstrated, except for a small increase in the number of free platelets after stimulation by HEPES. HEPES resembles the physiologically relevant effect of shear stress not related to the tested agonists. However, the observed difference between the GSE and placebo groups was small and therefore physiologically relevant is unclear. The lack of a clear effect may be partly due to the smaller dose of polyphenols used in the present study than the dose used in the two earlier studies. Future larger-sized studies should preferably test higher doses of GSE.

In summary, the present study shows that GSE rich in polyphenols has no major BP-lowering effect in middle-aged males and females with pre- and stage 1 hypertension. If anything, the effect is smaller than reported earlier. However, because even modest BP reductions of the order of 2 mmHg could have a significant impact on CVD at the population level\(^ {23}\), future larger-scale studies are warranted to further investigate the BP-lowering potential of grape seed polyphenols. These studies should preferably include subjects at an increased risk of CVD (e.g. metabolic syndrome patients) and measure BP over a 24 h period. Also, we recommend testing higher polyphenol doses with relatively more monomeric procyanidins, consumed twice per d.

**Supplementary material**

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/S000711451300161X

**Acknowledgements**

We would like to acknowledge Wieneke Koppenol for her contribution to the conduct of the study, Arne Jol and Michiel Gribnau for performing the statistics, Young de Graaf for the analysis of platelet aggregation and ADMA and Ferdi van Dorsten and Sonja Peters for the analysis of urinary polyphenols.


The present study was conducted and funded by Unilever R&D Vlaardingen, The Netherlands. R. T. R., P. L. Z. and R. D. are employed by Unilever R&D Vlaardingen. Y. E. M. P. Z. was employed by Unilever R&D Vlaardingen at the time of the study conduct. Unilever markets food products, some of which address cardiovascular risk factors. D. J. W. and N. R. J. had no conflicts of interest.

**References**


